Tagged: medical research
Taxol Dosing – new study
“The addition of new chemotherapy drugs has not improved outcomes. Thus, we need to give the active drugs in the best way,” says G. Thomas Budd MD of the Cleveland Clinic. Dr. Budd reported a very interesting study comparing two dosing regimens of Taxol (paclitaxel) at ASCO 2013, this year’s...
Pain is in the brain
Pain is much on my mind lately. As recently as last November I wrote a post (Pain) in which I talked about my reluctance to use narcotic pain relief. Recent readers of Telling Knots will know that I have since agreed to take the stuff in spite of my objections....
Seriously, MD Anderson Cancer Center?
Today it is my great pleasure to reblog this post from the American neurologist who blogs at Doctor Grumpy in the House. (It is a great blog with humor, honesty, humanity and all kinds of good stuff that does not necessarily begin with H. You should read it.) This post,...
Breast Surgery News
With thanks to Dr. Deanna Attai, a California breast surgeon and the new Secretary-Treasurer and member of the Executive Committee of The American Society of Breast Surgeons, who posted this on her Facebook page, I’d like to draw your attention to this article in the Seattle Times, by Marilynn Marchione, AP Chief Medical...
The Komen Organization in Numbers and Words
I love the Internet! With thanks to my friend GG, a stellar webcomber, I have been spending the last couple of days studying the most recent independent audit of the Susan G. Komen Breast Cancer Foundation, Inc. The audit is available to all as a PDF at that link. First,...
“Metastatic work is a waste of time.”
With thanks to Nancy Stordahl of Nancy’s Point for posting it on Facebook, I’d like to draw everyone’s attention to a spot-on article on Salon: The ultimate cancer taboo: Sometimes it kills you by Mary Elizabeth Williams. If anyone wonders why people with metastatic cancer sometimes (often) feel like the red-headed stepchildren of the...
Long-term Role of SERMs in Preventing Recurrence of Breast Cancer
A meta-analysis published in The Lancet looked at the role of SERMs (Selective Estrogen Receptor Modulators) and found that they do indeed play a role in reducing incidence of breast cancer recurrence for as many as ten years after initial diagnosis and treatment, with the greatest benefit in the first...